logo

NEPHROPLUS vs VIVIMEDLAB: Stock Comparison

NEPHROCARE HEALTH SERV L vs VIVIMEDLABUpdated 19 Oct 26, 4:08 PM ISTNSE & company filings

NEPHROCARE HEALTH SERV L is the larger company by market capitalisation. NEPHROCARE HEALTH SERV L shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

NEPHROPLUS leads 9; VIVIMEDLAB leads 0 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

NEPHROPLUSVIVIMEDLAB

Valuation lens

What price are you paying?

Market CapContext only
₹6,124 Cr
₹53 Cr
P/E RatioSame reading
79.5x
—
P/B RatioSame reading
5.47x
—
EPSNEPHROPLUS has the higher reading
₹3.19 ✓
₹-17.61
Book ValueContext only
₹111.27
—
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
NEPHROPLUS is the larger company
₹6,124 Cr vs ₹53 Cr
EPS
NEPHROPLUS has higher earnings per share
₹3.19 vs ₹-17.61
Revenue Growth (TTM YoY)
NEPHROPLUS has faster revenue growth
0% vs -22.42%
Qtr Sales Growth
NEPHROPLUS has stronger quarterly sales growth
0% vs -24.95%
Qtr Profit Growth
NEPHROPLUS has stronger quarterly profit growth
0% vs -782.17%
ROE
NEPHROPLUS has a higher ROE
-0.83% vs -57.01%
ROCE
NEPHROPLUS has a higher ROCE
5.17% vs -5.3%
Net Margin
NEPHROPLUS has a higher net margin
7.69% vs -27.09%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNEPHROPLUSVIVIMEDLAB
Sector—Healthcare
Industry—Pharmaceuticals

Price

MetricNEPHROPLUSVIVIMEDLAB
Live Price₹611.55₹7.39
Day Change-0.46%-3.15%
Volume1.53 L1.47 L
52-Week High₹781.5₹20.59
52-Week Low₹446₹5.15
Distance from 52W High-21.75%-64.11%

Valuation

MetricNEPHROPLUSVIVIMEDLAB
Market Cap₹6,124 Cr₹53 Cr
P/E Ratio79.5x—
P/B Ratio5.47x—
EPS₹3.19₹-17.61
Book Value₹111.27—
Dividend Yield0%0%

Growth

MetricNEPHROPLUSVIVIMEDLAB
Revenue Growth (TTM YoY)0%-22.42%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%-24.95%
Qtr Profit Growth0%-782.17%

Profitability & Leverage

MetricNEPHROPLUSVIVIMEDLAB
ROE-0.83%-57.01%
ROCE5.17%-5.3%
Net Margin7.69%-27.09%
Operating Margin7.3%-40.67%
Debt to Equity0.01x8.29x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricNEPHROPLUSVIVIMEDLAB
Promoter Holding18.79%▼ 2.28 pp7.57%▼ 0.2 pp
FII Holding11.73%▲ 2.95 pp1.64%
DII Holding8.11%▼ 0.94 pp0%
Public Holding21.85%▲ 3.53 pp90.67%▲ 0.19 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NEPHROCARE HEALTH SERV L and VIVIMEDLAB.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.